Ontology highlight
ABSTRACT:
SUBMITTER: Ezat AA
PROVIDER: S-EPMC6531565 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
Ezat Ahmed A AA Elfiky Abdo A AA Elshemey Wael M WM Saleh Noha A NA
Virusdisease 20190321 2
In 2011, the FDA approved boceprevir as a hepatitis C virus (HCV) NS3 serine protease inhibitor. The sustained virological response rate for treatment with this approved compound is considerably low. Patients have not responded as much as expected to boceprevir therapy. In this in silico study, modified boceprevir compounds are suggested and tested on wild-type HCV NS3 protease and 19 mutated HCV NS3 proteases using molecular docking. Results reveal the superiority of two of the proposed modifie ...[more]